David P Adam
Overview
Explore the profile of David P Adam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruce J, Burr A, Kimple R, Adam D, Yu M, Piaskowski S, et al.
EBioMedicine
. 2024 Dec;
111():105496.
PMID: 39671752
Background: Re-irradiation of recurrent head and neck cancer (HNC) is often limited by tumour adherence to critical structures and/or radiation tolerance of critical normal tissues. Iopofosine I 131 (CLR 131)...
2.
Su L, Huang E, Miles D, Farjam R, Marsh I, Li Q, et al.
J Appl Clin Med Phys
. 2024 Aug;
25(10):e14485.
PMID: 39190567
Purpose: A single treatment planning system (TPS) model for matched linacs provides flexible clinical workflows from patient treatment to intensity-modulated radiation therapy (IMRT) quality assurance (QA) measurement. Since general guidelines...
3.
Kerr C, Sheehan-Klenk J, Grudzinski J, Adam D, Nguyen T, Ferreira C, et al.
bioRxiv
. 2024 Jul;
PMID: 39071353
Teaser: This study describes the time course and nature of tumor immunomodulation by radiopharmaceuticals with differing physical properties.
4.
Adam D, Grudzinski J, Marsh I, Hill P, Cho S, Bradshaw T, et al.
Int J Radiat Oncol Biol Phys
. 2024 Feb;
119(4):1275-1284.
PMID: 38367914
Purpose: Targeted radiopharmaceutical therapy (RPT) in combination with external beam radiation therapy (EBRT) shows promise as a method to increase tumor control and mitigate potential high-grade toxicities associated with re-treatment...
5.
Sodji Q, Forsberg M, Cappabianca D, Kerr C, Sarko L, Shea A, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201618
Chimeric antigen receptor (CAR) T cells have been relatively ineffective against solid tumors. Low-dose radiation which can be delivered to multiple sites of metastases by targeted radionuclide therapy (TRT) can...
6.
Adam D, Hammer C, Malyshev J, Culberson W, Bradshaw T, Grudzinski J, et al.
Biomed Phys Eng Express
. 2023 Apr;
9(4).
PMID: 37084718
Voxel-level dosimetry based on nuclear medicine images offers patient-specific personalization of radiopharmaceutical therapy (RPT) treatments. Clinical evidence is emerging demonstrating improvements in treatment precision in patients when voxel-level dosimetry is...
7.
Stasko J, Ferris W, Adam D, Culberson W, Frigo S
J Appl Clin Med Phys
. 2023 Apr;
24(8):e13990.
PMID: 37031363
Background: Quality assurance measurement of IMRT/VMAT treatment plans is resource intensive, and other more efficient methods to achieve the same confidence are desirable. Purpose: We aimed to analyze treatment plans...
8.
Marsh I, Li C, Grudzinski J, Jeffery J, Longhurst C, Adam D, et al.
Cancer Biother Radiopharm
. 2023 Apr;
38(7):458-467.
PMID: 37022739
Delivery of radiotherapeutic dose to recurrent head and neck cancer (HNC) is primarily limited by locoregional toxicity in conventional radiotherapy. As such, HNC patients stand to benefit from the conformal...
9.
Adam D, Grudzinski J, Bormett I, Cox B, Marsh I, Bradshaw T, et al.
Med Phys
. 2022 May;
49(8):5491-5503.
PMID: 35607296
Purpose: Approximately 50% of head and neck cancer (HNC) patients will experience loco-regional disease recurrence following initial courses of therapy. Retreatment with external beam radiotherapy (EBRT) is technically challenging and...
10.
Adam D, Bednarz B, Frigo S
J Appl Clin Med Phys
. 2022 May;
23(8):e13646.
PMID: 35596533
Purpose: We investigated the hypothesis that the transmission function of rounded end linearly traveling multileaf collimators (MLCs) is constant with position. This assumption is made by some MLC models used...